Literature DB >> 10604141

Blood lipids and endothelial function in glycogen storage disease type III.

E Hershkovitz1, A Donald, M Mullen, P J Lee, J V Leonard.   

Abstract

We have assessed early indicators of arterial disease in patients with glycogen storage disease type III (GSD III; McKusick 232400), investigating the plasma lipid and lipoprotein profile and endothelial function. Eleven patients, aged 10-39 years, were recruited together with age-, sex- and smoking status-matched controls. Brachial artery responses were assessed by high-resolution ultrasonographic measurement of the diameter of the brachial artery at baseline, after reactive hyperaemia and in response to sublingual glyceryl trinitrate (GTN). The means of plasma cholesterol (total and HDL and LDL subfractions), triglycerides, apo-A1, apo-B, Lp(a) and the atherogenic index were similar in both groups. Cardiac troponin I was below the lower limits of detection (< 0.03 g/L) in all subjects. The GSD III patients had similar body mass index (BMI) and brachial artery diameter to the control group (BMI 22.6 +/- 5.6 vs 22.3 +/- 5 kg/m2; brachial artery diameter 3.4 +/- 0.5 vs 3 +/- 0.7 mm). When compared to the baseline diameter, the maximal flow-mediated dilatation of the brachial artery after reactive hyperaemia was 9.3% +/- 2.1% (mean +/- SD) in the GSD III patients and 6.5% +/- 3.5% in the control group, a difference of 1.8% (95% CI 0.07% to 5.5%). The maximal dilatation of the brachial artery after GTN administration was 18.3% +/- 6.4% in the GSD III patients and 17.9% +/- 6.5% in the control group, a difference of 0.4% (95% CI-6.9% to 7.7%). In conclusion, we found no evidence of abnormal plasma lipid and lipoprotein profile or endothelial dysfunction in patients with GSD III. They are unlikely to be at increased risk of premature atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10604141     DOI: 10.1023/a:1005687323096

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  29 in total

1.  Blood lipids and rheological modifications in glycogen storage disease.

Authors:  K Keddad; S M Razavian; C Baussan; J Chalas; A Abella; J Levenson; A Simon; N Moatti; A Legrand
Journal:  Clin Biochem       Date:  1996-02       Impact factor: 3.281

2.  Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels.

Authors:  P Clarkson; D S Celermajer; A E Donald; M Sampson; K E Sorensen; M Adams; D K Yue; D J Betteridge; J E Deanfield
Journal:  J Am Coll Cardiol       Date:  1996-09       Impact factor: 24.094

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  Amino acid disturbances in type III glycogenosis: differences from type I glycogenosis.

Authors:  A E Slonim; R A Coleman; S Moses; N Bashan; E Shipp; P Mushlin
Journal:  Metabolism       Date:  1983-01       Impact factor: 8.694

5.  Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility.

Authors:  K E Sorensen; D S Celermajer; D J Spiegelhalter; D Georgakopoulos; J Robinson; O Thomas; J E Deanfield
Journal:  Br Heart J       Date:  1995-09

6.  Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.

Authors:  D S Celermajer; K E Sorensen; V M Gooch; D J Spiegelhalter; O I Miller; I D Sullivan; J K Lloyd; J E Deanfield
Journal:  Lancet       Date:  1992-11-07       Impact factor: 79.321

Review 7.  Glycogen storage disease in adults.

Authors:  G M Talente; R A Coleman; C Alter; L Baker; B I Brown; R A Cannon; Y T Chen; J F Crigler; P Ferreira; J C Haworth; G E Herman; R M Issenman; J P Keating; R Linde; T F Roe; B Senior; J I Wolfsdorf
Journal:  Ann Intern Med       Date:  1994-02-01       Impact factor: 25.391

Review 8.  Glucose-6-phosphate: a key compound in glycogenosis I and favism leading to hyper- or hypolipidaemia.

Authors:  G Schmitz; H Hohage; K Ullrich
Journal:  Eur J Pediatr       Date:  1993       Impact factor: 3.183

9.  Hyperlipidaemia does not impair vascular endothelial function in glycogen storage disease type 1a.

Authors:  P J Lee; D S Celermajer; J Robinson; S N McCarthy; D J Betteridge; J V Leonard
Journal:  Atherosclerosis       Date:  1994-09-30       Impact factor: 5.162

Review 10.  Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics.

Authors:  J A Berliner; M Navab; A M Fogelman; J S Frank; L L Demer; P A Edwards; A D Watson; A J Lusis
Journal:  Circulation       Date:  1995-05-01       Impact factor: 29.690

View more
  3 in total

1.  Hyperlipidemia in glycogen storage disease type III: effect of age and metabolic control.

Authors:  A V Bernier; C P Sentner; C E Correia; D W Theriaque; J J Shuster; G P A Smit; D A Weinstein
Journal:  J Inherit Metab Dis       Date:  2008-08-19       Impact factor: 4.982

2.  Characterization of a canine model of glycogen storage disease type IIIa.

Authors:  Haiqing Yi; Beth L Thurberg; Sarah Curtis; Stephanie Austin; John Fyfe; Dwight D Koeberl; Priya S Kishnani; Baodong Sun
Journal:  Dis Model Mech       Date:  2012-06-26       Impact factor: 5.758

3.  A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type III.

Authors:  Ghada Hijazi; Anna Paschall; Sarah P Young; Brian Smith; Laura E Case; Tracy Boggs; Sathya Amarasekara; Stephanie L Austin; Surekha Pendyal; Areeg El-Gharbawy; Kristen L Deak; Andrew J Muir; Priya S Kishnani
Journal:  Mol Genet Metab Rep       Date:  2021-11-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.